You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Dow
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,132,118

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,132,118
Title:Taxane analogs for the treatment of brain cancer
Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.
Inventor(s): McChesney; James D. (Etta, MS), Tapolsky; Gilles (Louisville, KY), Emerson; David L. (Longmont, CO), Marshall; John (Washington, DC), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tucson, AZ)
Assignee: Tapestry Pharmaceuticals, Inc. (Atlanta, GA)
Application Number:13/785,753
Patent Claims:1. A compound of the structure of formula (1): ##STR00026##

2. The compound of claim 1, wherein the compound of formula (1) is an isomer having the structure of formula R-(1): ##STR00027##

3. The compound of claim 1, wherein the compound of formula (1) is an isomer having the structure of formula S-(1): ##STR00028##

4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 further comprising one or more chemotherapeutic agents effective in the treatment of brain cancer.

6. The composition of claim 4 which further comprises temozolomide or bevacizumab.

7. The composition of claim 4 formulated for oral administration.

8. The pharmaceutical composition of claim 4, wherein the compound has the structure of formula S-(1): ##STR00029##

Details for Patent 9,132,118

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Tapestry Pharmaceuticals, Inc. (Atlanta, GA) 2027-02-28 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Tapestry Pharmaceuticals, Inc. (Atlanta, GA) 2027-02-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
Harvard Business School
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.